ClinicalTrials.gg
CompletedNCT02244255Updated Sep 19, 2014

FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia

A Phase 4 interventional study of FLOMAX® capsules and Ascending doses of HYTRIN® capsules in Prostatic Hyperplasia, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2014-09-19.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,993
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 48 studies testing tamsulosin in Prostatic Hyperplasia — 8 open to participants now, 8 under way, 1 of them phase 3. Tamsulosin · Prostatic Hyperplasia.

Enrollment
2nd of 48
1,993 · median 118
Started
1998
with 2 others
Phase 4
17 of 48
4 open now
Registered
19th of 48
by date
Lead sponsor
5 of 48
Boehringer Ingelheim

Among the 48 studies testing tamsulosin in Prostatic Hyperplasia, this one is the 2nd largest by enrollment, is one of 3 that started in 1998, is one of 17 in phase 4, and was the 19th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

8 of the 48 studies testing tamsulosin in Prostatic Hyperplasia are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About tamsulosin

Tamsulosin: first FDA approval 1997 (FLOMAX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing tamsulosin in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

  1. To study the early onset of symptomatic relief afforded by FLOMAX® capsules, 0.4 mg daily as compared to HYTRIN® capsules, 5 mg (with titration) daily in patients with the signs and symptoms of benign prostatic hyperplasia (BPH)
  2. To evaluate patient's tolerability to the use of FLOMAX® capsules 0.4 mg daily in comparison to HYTRIN® capsules, 5 mg (with titration) daily for the treatment of the symptoms of benign prostatic hyperplasia
03

Conditions studied

  • Prostatic Hyperplasia

Browse trials for

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male patients (45 years of age or older) diagnosed with benign prostatic hyperplasia
  • Patients with a total score on the AUA Symptom Index for BPH of at least 13 points at each of the three initial visits (Visits 1, 2 and 3)
  • A baseline prostate specific antigen (PSA) of ≤ 4.0 ng/ml
  • Patients who are able to give written before performing screening examinations or tests
  • Patients being judged by the investigator to be reliable and able to follow protocol procedures (including the return visits schedule), and cooperate in the completion of tests related to safety and efficacy

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of an allergy to alpha blockers, alpha/beta blockers or patients who have had a "first dose hypotensive episode" upon starting therapy with an alpha blocker
  • Patients who are currently being treated or who, in the last 3 months, have been treated with finasteride
  • Participated in an drug study within 4 weeks prior to starting placebo phase
  • Patients taking medication in the following classes and unable to discontinue them at least two weeks before the study and for the duration of the study

    • Alpha adrenergic blocking agents
    • Alpha adrenergic agonists
    • Drugs with anticholinergic activity (including antihistamines)
    • Antispasmodics
    • Parasympathomimetics and cholinomimetics
  • Peripheral or central neurologic disease including, but not limited to, , stroke, dementia, multiple sclerosis, spinal cord injury, recurrent episodes of dizziness, vertigo, or loss of consciousness, clinically evident diabetic neuropathy, brain and/or spinal cord tumors
  • History of a pathological fall (unintentional change in body position) occurring under circumstances in which normal homeostatic mechanisms would ordinarily maintain stability, or syncope during the last year
  • More than one episode of angina within the past 6 months
  • Ambulation requiring assistance (i.e., canes, walkers, etc.)
  • Documented myocardial infarction (by ) within the past 6 months or evidence of a myocardial infarction on ECG whose age cannot be determined
  • Class III or IV congestive heart failure
  • Prosthetic heart valves, cardiac devices or prior history of endocarditis
  • cardiac arrhythmias either diagnosed by ECG or recorded in the medical history, whether or not accompanied by symptoms (e.g., dizziness, presyncope, syncope, unsteadiness)
  • Infravesical obstruction by history due to:

    • Vesical neck contracture
    • Clinical suspicion of prostate carcinoma
    • Mullerian duct cysts
    • Urethral obstruction due to stricture, valves, sclerosis or urethral tumor
    • Inflammatory or infectious conditions
    • Detrusor-sphincter dyssynergia
  • Prior transurethral resection of the prostate (TURP) or open prostatectomy
  • History of instrumentation of the urinary tract (cytoscopy or catheterization) within 30 days prior to the start of the study
  • Prior pelvic surgery for or bowel resection
  • History or diagnosis of genitourinary malignancy
  • History of an episode of acute urinary retention within three months prior to the start of the study. (Urinary retention is to be considered acute if the patient has to be sent to a hospital for catheterization)
  • Patients with the current diagnosis of either bladder, ureter, or kidney stones
  • Patients with a current diagnosis of suspected prostatitis
  • Patients with a history of a neurogenic bladder
  • Urinary tract infection (i.e., positive urine culture) yielding pathogenic bacteria > 10**5 colony forming units (CFU) per milliliter in a properly obtained clean voided urine specimen which has been properly cultured or a laboratory report of a urinary tract infection or signs/symptoms indicative of a urinary tract infection such as [increased WBC's in the urine (15-30 white blood cells (WBC)/high powered field), dysuria, costovertebral tenderness, and urinary frequency accompanied by fever] within four weeks of baseline (Visit 3)
  • Evidence of significant renal dysfunction based upon a serum creatinine greater than two times the levels established by the central laboratory used in this study
  • Laboratory tests during the screening phase:

    • : \< 12.0 g/dL
    • Leukocytes: \< 3000/mm3
    • Liver Enzymes: (serum glutamic oxaloacetic transaminase (), serum glutamate pyruvate transaminase (SGPT), and alkaline phosphatase): more than two times the upper limit of normal levels established by the central laboratory used in the study
  • Clinically relevant conditions which might interfere with the patient's ability to participate in the study including, but not limited to, the following: neurologic, gastrointestinal, cardiovascular including uncontrolled hypertension defined as a sitting diastolic blood pressure ≥ 95 mmHg with or without treatment, hepatic, renal, psychiatric, hematologic or respiratory disease, clinically relevant laboratory abnormalities based upon the investigator's judgment
  • Hypertensive patients initially using HYTRIN® as a monotherapy for both hypertension and BPH
  • Patients with cancer or diagnosis of cancer within five years of baseline
  • Patients who have been receiving cimetidine, warfarin, or herbal medications specifically for treatment of any urological problems within four weeks prior to the baseline
  • Patients who show poor compliance in the initial placebo period by:

    • not returning unused medication bottles for Visits 2 or 3
    • having taken \< 80% or > 120% of prescribed doses during any visit interval between Visit (1, 2 or 3)
  • Postural symptoms during the initial placebo period, e.g., lightheadedness (on more than three occasions), fainting, blurring or loss of vision, profound weakness, or unsteadiness, with or without a change in blood pressure and/or pulse rate
  • Patients with poorly controlled diabetes mellitus (urine positive for glucose (> 1+) on each of 2 urinalyses during the placebo evaluation period)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,993 participants (actual)

Study arms

  • Experimental
    FLOMAX®

    Drug: FLOMAX® capsules

  • Active comparator
    HYTRIN®

    Drug: Ascending doses of HYTRIN® capsules

Interventions

  • Also known as: Tamsulosin hydrochloride

  • DrugAscending doses of HYTRIN® capsules
06

What researchers measure

Primary outcomes

  1. Changes in American Urological Association (AUA) symptom score index

    Time frame: Pre-dose, up to day 57 after start of treatment

Secondary outcomes

  1. Changes in AUA bother score index

    Validated quality of life questionnaire for urinary problems containing: * AUA obstructive symptom score * AUA irritative symptom score * AUA nocturia symptom score

    Time frame: Pre-dose, up to 57days after start of treatment

  2. Changes in BPH impact index score

    Time frame: Pre-dose, up to 57 days after start of treatment

  3. Global assessment by investigator on a 5-point scale

    Time frame: Day 5, up to day 57 after start of treatment

  4. Number of patients with clinically relevant changes from baselinein laboratory values

    Time frame: Pre-dose, day 57 after start of treatment

  5. Number of patients with clinically significant changes in vital signs

    Time frame: Pre-dose, up to 57 days after start of treatment

  6. Number of patients with clinically relevant changes from baseline in ECG

    Time frame: Pre-dose, up to 57 days after start of treatment

  7. Number of patients with adverse events

    Time frame: Up to day 57

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 1998 and a primary completion of Jun 2000. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2014
First posted
Sep 19, 2014
Start
Aug 1998
Primary completionActual
Jun 2000
Last update
Sep 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02244255
Responsible party
Sponsor
First posted
Sep 19, 2014
Start date
Aug 1998
Primary completion
Jun 2000
Last update
Sep 19, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamsulosin

Start the discussion